Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
PGDH Double Nickase Plasmid (h): sc-402622-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- PGDH Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- PGDH Double Nickase Plasmid (h) and PGDH Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting HPGD. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: PGDH Antibody (H-3): sc-271418
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PGDH Double Nickase Plasmid (h) | sc-402622-NIC | 20 µg | $410.00 | |||
PGDH Double Nickase Plasmid (h2) | sc-402622-NIC-2 | 20 µg | $410.00 |
Human HPGD encodes 15-hydroxyprostaglandin dehydrogenase (PGDH), a key NAD+-dependent oxidoreductase that catalyzes the first and rate-limiting step in prostaglandin and other eicosanoid inactivation. By converting bioactive prostaglandins such as PGE2 into less active 15-keto metabolites, PGDH helps restrain inflammatory signaling, modulate vascular tone, and shape epithelial homeostasis within arachidonic acid metabolism. Altered HPGD activity can shift prostaglandin-driven pathways that influence cytokine networks, stromal-epithelial crosstalk, and tissue remodeling. Dysregulation of this axis is frequently investigated in contexts including chronic inflammation and cancer biology, where prostaglandin turnover impacts cell proliferation, migration, and microenvironmental signaling.
PGDH Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the HPGD locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within HPGD. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt HPGD function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of HPGD-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.